Wells Fargo analyst Eva Fortea Verdejo raised the firm’s price target on Zymeworks (ZYME) to $25 from $17 based on recent news, while keeping an Equal Weight rating on the shares. The firm thinks there is value in the partnership approach, but is cautious on the royalty-driven strategy beyond zani until it gets more clarity.
TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ZYME:
- Zymeworks price target raised to $40 from $30 at Stifel
- Zymeworks’ Promising Phase 3 Results Drive Buy Rating for HER2-Positive Cancer Treatment
- Zymeworks Appoints Scott Platshon as Acting CIO
- Zymeworks price target raised to $32 from $26 at H.C. Wainwright
- Zymeworks announces new $125M share repurchase plan